2. Search Result
Search Result
Results for "

thiazolidinedione

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-59272
    2,4-Thiazolidinedione

    		Biochemical Assay Reagents Others
    2,4-Thiazolidinedione is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    2,4-<em>Thiazolidinedione</em>
  • HY-14928A
    Lobeglitazone sulfate

    		Others Metabolic Disease
    Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate can be used to prevent type 2 diabetes mellitus (T2DM) .
    Lobeglitazone sulfate
  • HY-100550
    MSDC 0160
    2 Publications Verification

    Mitoglitazone; CAY10415

    		 Insulin Receptor Mitochondrial Metabolism Neurological Disease Endocrinology
    MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease .
    MSDC 0160
  • HY-131044
    5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione

    		Bacterial Fungal Infection
    5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione (Compound 4) has antimicrobial, anti-diabetic and antioxidant activities. 5-[(2-Nitrophenyl)methylene]-2,4-thiazolidinedione inhibits B. subtilis, S. aureus, K. pneumonia, E. coli, and S. typhi with MICs of 4.5-9.9 μΜ/mL, and inhibits A. niger and C. albicans with MICs of 4.99 μΜ/mL .
    5-[(2-Nitrophenyl)methylene]-2,4-<em>thiazolidinedione</em>
  • HY-14928
    Lobeglitazone

    		Others Metabolic Disease
    Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM) .
    Lobeglitazone
  • HY-120160
    Darglitazone

    CP-86325

    		 PPAR Neurological Disease Metabolic Disease
    Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
    Darglitazone
  • HY-120160A
    Darglitazone Sodium

    CP 86325 Sodium

    		 PPAR Neurological Disease Metabolic Disease
    Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
    Darglitazone Sodium
  • HY-106181
    Rivoglitazone

    R-106056

    		 PPAR Metabolic Disease
    Rivoglitazone is a thiazolidinedione-derivative PPARγ agonist for the research of type 2 diabetes mellitus.
    Rivoglitazone
  • HY-155823
    TZ4M

    		Cholinesterase (ChE) Neurological Disease
    TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model .
    TZ4M
  • HY-108022
    Azemiglitazone

    MSDC-0602

    		 Mitochondrial Metabolism PPAR Neurological Disease Metabolic Disease Inflammation/Immunology
    Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury .
    Azemiglitazone
  • HY-101292
    FK614

    		PPAR Metabolic Disease
    FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .
    FK614
  • HY-100277
    Mifobate
    1 Publications Verification

    SR-202

    		 PPAR Metabolic Disease
    Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects .
    Mifobate
  • HY-108022A
    Azemiglitazone potassium

    MSDC-0602K

    		 Insulin Receptor PPAR Metabolic Disease
    Azemiglitazone potassium (MSDC-0602K), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM . Azemiglitazone potassium modulates the mitochondrial pyruvate carrier (MPC). Azemiglitazone potassium can be used for the research of fatty liver including dysfunctional lipid metabolism, inflammation, and insulin resistance . Azemiglitazone potassium, an insulin sensitizer, improves insulinemia and fatty liver disease in mice, alone and in combination with Liraglutide .
    Azemiglitazone potassium
  • HY-151352
    DHDPS-IN-1

    		Bacterial Infection
    DHDPS-IN-1 (compound 8) is a DHDPS inhibitor (IC50: 39 μM). DHDPS-IN-1 can be used in the area of antibacterial and herbicidal .
    DHDPS-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: